NCT00547352已完成4 期
Switching From Sildenafil Citrate to Tadalafil in Treatment of Erectile Dysfunction: Assessment of Treatment Preference
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 160
- 试验地点
- 1
- 主要终点
- Patient choice of drug at visit 5
研究概览
简要总结
To determine if men with problems getting and keeping an erection prefer treatment with tadalafil or sildenafil.
研究设计
- 研究类型
- Interventional
- 干预模型
- Crossover
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •History of erection problems
- •Anticipate a monogamous female sexual relationship
- •Abstain from other erection treatments throughout the study
- •Currently use sildenafil
排除标准
- •Other primary sexual disorders
- •History of radical prostatectomy or other pelvic surgery that affected being able to have an erection
- •History of penile implant or clinically significant penile deformity.
- •Nitrate use
- •Certain heart problems
研究组 & 干预措施
1
Active Comparator
sildenafil treatment for at least 10 weeks prior to a 1 week wash out
干预措施: sildenafil (Drug)
2
Active Comparator
Tadalafil treatment for 8 weeks following the 1 week washout period.
干预措施: tadalafil (Drug)
结局指标
主要结局
Patient choice of drug at visit 5
时间窗: 14-15 weeks
次要结局
- PAIRS self-administered scale scores(14-15 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Studying the Preference of Tadalafil to Sildenafil in Men With Problems Getting an Erection Across NationsImpotenceNCT00547287Eli Lilly and Company2,760
已完成
4 期
Study For Which Treatment, Tadalafil or Sildenafil, is Preferred For Problems Getting or Maintaining an ErectionImpotenceNCT00547092Eli Lilly and Company386
已完成
2 期
Comparison of Sildenafil and Tadalafil in the treatment of benign prostatic hyperplasiaBenign prostatic hyperplasia (BPH).Enlarged prostate with lower urinary tract symptomsN40.1IRCT20210925052576N1Islamic Azad University66
已完成
4 期
A Study of Tadalafil and Sildenafil in Men With Erectile Dysfunction in ChinaErectile DysfunctionNCT01352507Eli Lilly and Company383
尚未招募
不适用
Comparative analysis of Sildenafil and Tadalafil in erectile dysfunctioCTRI/2023/01/048951ot applicable